We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 8,478

Wrong number for Napp Pharmaceuticals in UK Buprenorphine infringement cases
  • AA Thornton & Co
  • European Union, United Kingdom
  • June 20 2017

Napp Pharmaceuticals (Napp) is the proprietor of a European (UK) patent, EP2305194B (the Patent), which provides protection for transdermal


Cleveland Clinic Decision Highlights Catch-22 Of Personalized Medicine Patents
  • Foley & Lardner LLP
  • USA
  • June 20 2017

The Federal Circuit decision in Cleveland Clinic Foundation v. True Health Diagnostics LLC, strikes another blow against the patent eligibility of


Supreme Court overturns the Federal Circuit, granting more flexibility to biosimilar makers
  • Thompson Coburn LLP
  • USA
  • June 20 2017

In a unanimous opinion, the United States Supreme Court again reversed the Federal Circuit in Sandoz Inc. v. Amgen Inc., interpreting the meaning of


Opportunity knocks: How the overhaul of the National Health and Medical Research Council (NHMRC) grants scheme and IP can open new doors to more academics than before
  • Watermark Patent & Trade Marks Attorneys
  • Australia
  • June 20 2017

On Thursday 25 May the Minister for Health, the Hon. Greg Hunt MP, and the National NHMRC CEO, Professor Anne Kelso announced a complete overhaul of


The Challenges Surrounding Patenting 3-D Bioprinted Organ and Tissue Technology
  • Hogan Lovells
  • USA
  • June 20 2017

In this hoganlovells.com interview, New York-based partner Arlene Chow talks about the emergence of 3-D bioprinting and the ability of innovators in


Key issues in building life sciences patent portfolios
  • NLO
  • Global
  • June 20 2017

The financial success of a life sciences company depends primarily on the scope, lifetime and strength of its patent portfolio. Successful life


Update: How the U.S. Compares to Europe on Biosimilar Approvals and Products In the Pipeline
  • Rothwell, Figg, Ernst & Manbeck, PC
  • European Union, USA
  • June 20 2017

As pharmaceutical drug costs attract increasing media attention and political scrutiny, a growing number of biosimilar drugs are set to enter the U.S


Five Years After Mayo v. Prometheus: Where Do We Go From Here?
  • Pearl Cohen Zedek Latzer Baratz LLP
  • USA
  • June 19 2017

In 1980, the Supreme Court - in Diamond v. Chakrabarty, 100 S.Ct. 2204 (1980) in a 5-4 decision - held that a recombinant microorganism was


Patent Trial and Appeal Board Affirms Motion for Judgment to Pepper Hamilton Client
  • Pepper Hamilton LLP
  • Canada, USA
  • June 16 2017

The Patent Trial and Appeal Board affirmed that the board correctly granted a motion for judgment to a specialty pharmaceutical company after finding


Sandoz Inc. v. Amgen Inc.
  • Merchant & Gould
  • USA
  • June 16 2017

In a unanimous decision in Sandoz Inc. v. Amgen Inc., the U.S. Supreme Court held that injunctive relief was not available under federal law to